CB7630 abiraterone acetate: Additional Phase I data

Data from the open-label, U.S. Phase I COU-AA-002 trial in 30 evaluable patients showed that once-daily CB7630 reduced PSA levels in 27 patients (90%); 16 (53%) had a >50% PSA decline. In 11 ketoconaz...